Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)


Phase 3 Results

Eligibility Criteria

Inclusion Criteria

- > or = 18 years of age
- Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG documentation)
- Able to swallow pill form of drug

Exclusion Criteria

- < 18 years of age
- enrollment in another ongoing trial
- paroxysmal atrial fibrillation
- hemodynamic instability
- atrial fibrillation ablation within 6 months of enrollment
- a contraindication for anticoagulation
- severe valvular heart disease
- presence of single lead implantable cardioverter defibrillator
- unstable angina
- New York Heart Association (NYHA) Class IV heart failure
- hyperthyroidism
- uncontrolled hypertension (blood pressure > 180/100 at rest) on medications
- an illness that would limit life expectancy to less than 1 year
- use of statins within the previous 30 days
- significant coronary artery disease or lipid abnormalities necessitating statin therapy
- implanted devices for active management of arrhythmias by pacing or defibrillation
- lack of access to a telephone
- illicit drug use
- alcohol abuse
- hypersensitivity to atorvastatin by history
- pregnancy
- sexually active female subjects not on contraception or surgically sterilized
- nursing mothers
- chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the upper limit of normal [ULN] of laboratory reference range)
- severe renal disease (creatinine > 200 mmol/L)
- inflammatory muscle disease or creatine kinase (CK) > 3 times ULN
- concurrent treatment with cyclosporine, fibrates, or high-dose niacin